Mesoblast’s Strong Financial Move: Retires Senior Debt
Mesoblast has refinanced its balance sheet with a new five-year, interest-only credit facility at a fixed 8% rate, drawing...
No videos found.
BiomX Announces Important $3.0 Million Private Placement
BiomX has secured a $3 million private placement anchored by Series Y convertible preferred stock and five-year warrants, a...
Tonix Announces Pricing for New $20M Direct Offering
Tonix Pharmaceuticals has secured approximately $20 million in gross proceeds through a direct offering to Point72, selling 615,025 common...
Tonix Reveals New Hope for Seasonal Lyme Disease Prevention
Tonix Pharmaceuticals has outlined a 2026 FDA engagement to shape a Phase 2/3 path for TNX-4800, a long-acting monoclonal...
Transcenta Collaboration to Advance Affordable Biomanufacturing
Transcenta has entered a strategic collaboration and non-exclusive licensing agreement with EirGenix to deploy Transcenta’s Highly Intensified Continuous Bioprocessing...
Announcing Management Change at NTG Nordic Transport Group
NTG Nordic Transport Group has appointed Tinneke Torpe as Group CFO, effective no later than April 1, 2026, while...
Genmab Announces Closing of Senior Notes Private Offering
Genmab has closed a $2.5 billion notes offering—$1.5 billion of 6.250% senior secured notes due 2032 and $1.0 billion...
NKGen Biotech Issues Statement on Affiliate Board Changes
NKGen Biotech’s majority-owned subsidiary in Seoul has overhauled its governance and identity. NKGen Biotech Korea, formerly NKMAX, completed a...
Nicox’s NCX 470 Data Complete for 2026 Drug Application
Nicox has completed the clinical and long-term stability data package required to support New Drug Applications for NCX 470,...
Nicox Finalizes Key NCX 470 Data for H1 2026 Filing
Nicox has completed all clinical and long‑term stability datasets required to support new drug applications for NCX 470, a...